

Gordon Dunn Report— November 2018

1. Clovis Oncology Receives Breakthrough Therapy Designation for Rubraca® (rucaparib) for Treatment of BRCA1/2-Mutated Metastatic Castration Resistant Prostate Cancer (mCRPC):

<https://www.pcf.org/news/clovis-oncology-receives-breakthrough-therapy-designation-for-rubraca-rucaparib-for-treatment-of-brca1-2-mutated-metastatic-castration-resistant-prostate-cancer-mcrpc/>

2. Immunotherapy could offer hope for some men with aggressive prostate cancers:

<https://www.pcf.org/news/immunotherapy-could-offer-hope-for-some-men-with-aggressive-prostate-cancers/>

3. Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.:

<https://www.ncbi.nlm.nih.gov/pubmed/30370697>

Note; These papers are available from the National Center for Biotechnology Information. All papers available at the NCBI website should have peer reviewed papers from legitimate research organizations. If you see ads for miracle cures for prostate cancer you can always check this site to see if there are legitimately published studies on the “miracle cure”.

<https://www.ncbi.nlm.nih.gov/>